![Anti-ATG13 [ATG13]](https://cancertools.org/wp-content/uploads/f5ddf649-3e1a-48b2-9674-7d356a023b1b.jpg)
Cat. #151612
Anti-ATG13 [ATG13]
Cat. #: 151612
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: ATG13
Class: Polyclonal
Application: WB
Reactivity: Human
Host: Rabbit
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Sharon Tooze
Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-ATG13 [ATG13]
- Research fields: Apoptosis and autophagy;Cancer;Cell signaling and signal transduction;Metabolism
- Clone: ATG13
- Tool sub type: Primary antibody
- Class: Polyclonal
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Rabbit
- Application: WB
- Description: Atg13 only binds in the unphosphorylated state, and its dephosphorylation has been shown to be TOR dependent.
- Immunogen: C-terminal synthetic peptide
Target Details
- Target: ATG13
- Target background: Autophagy has been implicated in a number of medical contexts, such as cancer, neurodegeneration, and immunity. The serine-threonine protein kinase Atg1 was originally identified as a critical autophagy regulator in yeast. Full kinase activity of Atg1 in yeast requires its binding partners Atg13 and Atg17.
Applications
- Application: WB
Handling
- Format: Liquid
- Unit size: 100 ug
- Shipping conditions: Dry ice
References
- Chan et al. 2009. Mol Cell Biol. 29(1):157-71. PMID: 18936157.
- Kinase-inactivated ULK proteins inhibit autophagy via their conserved C-terminal domains using an Atg13-independent mechanism.
